Extensive financial links between the leaders of US oncology professional associations and the pharmaceutical industry have raised concerns over independence and integrity.
More than A$84 million (US$55.6m) in industry payments flowed to leaders of the American Society of Clinical Oncology (ASCO) over a five year period according to figures published in BMJ.
Oncologists were ahead of other groups such as the American College of Cardiology ($35m) and the American College of Rheumatology ($26m) in the amount of industry financial support, according to the analysis of publicly available Open Payments transparency databases conducted by researchers from Bond University, Queensland.
The vast majority of the industry funding ($79.5m) to the ASCO leaders was payments for research, with only $2.2m in general industry payments for fees for consultancy, speaking, royalties and hospitality.
The analysis showed that almost all leaders of the ASCO (80% of the 33 clinicians) had financial ties to industry, with median payments to individuals of $763,000 and payments ranging from $200,000 to $2.89m.
Other professional associations whose leaders had high levels of financial payments from industry included the the North American Spine Society ($16m) and the Endocrine Society ($10.5m).
The study’s lead researcher, Dr Ray Moynihan from Bond University’s Institute for Evidence-Based Healthcare, said the financial links raised serious concerns about the independence of medical associations and societies influential in areas of research, education, and practice, including guideline development.
“I was surprised by the extent of the money flowing to these medical leaders, overall US$130 million to around 300 leaders over a roughly five-year period, it’s an enormous amount of money and an enormous amount of influence.